No Data
No Data
These 4 Measures Indicate That Haisco Pharmaceutical Group (SZSE:002653) Is Using Debt Reasonably Well
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the permanent loss of capital.' When we think about how risky a company is, we always like
What Haisco Pharmaceutical Group Co., Ltd.'s (SZSE:002653) 26% Share Price Gain Is Not Telling You
Haisco Pharmaceutical Group Co., Ltd. (SZSE:002653) shareholders would be excited to see that the share price has had a great month, posting a 26% gain and recovering from prior weakness. Longer-te
HiCisco (002653.SZ): Proposed capital increase for subsidiary HiCisco of the United States
HiCisco (002653.SZ) announced that its subsidiary, Sichuan Hisco Pharmaceutical Co., Ltd. (“Sichuan HiCisco”), used its own capital to fund its subsidiary HAISCO HOLDINGS PTE.LTD. (hereinafter referred to as “Hisco Holdings”) increased its capital by US$40 million.
HiCisco (002653.SZ): Innovative drug HSK39775 tablets approved for clinical trials
HiCisco (002653.SZ) announced that Tibet Hisco Pharmaceutical Co., Ltd., a subsidiary of the company (hereinafter referred to as the “Company”), recently received the “Drug Clinical Trial Approval Notice” issued by the State Drug Administration. HSK39775 tablets, intended for the treatment of advanced solid tumors.
Has Haisco Pharmaceutical Group Co., Ltd.'s (SZSE:002653) Impressive Stock Performance Got Anything to Do With Its Fundamentals?
Haisco Pharmaceutical Group (SZSE:002653) has had a great run on the share market with its stock up by a significant 5.7% over the last month. We wonder if and what role the company's financials pla
HiCisco (002653.SZ) plans to establish a wholly-owned subsidiary in Australia to promote clinical research of products overseas
Zhitong Financial App News, HiCisco (002653.SZ) announced that the 10th meeting of the 5th board of directors of the company reviewed and passed the “Proposal on the Company's Establishment of a Wholly-owned Subsidiary in Australia”, agreeing that the company's wholly-owned subsidiary Haisco Holdings Group Limited (“Hisco Holding Group”) plans to establish its wholly-owned subsidiary HAISCO INNOVATIVE PHARMACEUTICAL (AUSCO) PTY in Australia with its own capital of 50,000 Australian dollars LTD. (Proposed name).
No Data